On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Stellar Biotechnologies, Inc. (SBOTF) Fully Embracing Social Media as KLH Immunotherapy Really Comes into Its Own

Stellar Biotech is the industry leader in the field of sustainably manufacturable Keyhole Limpet Hemocyanin, or KLH, a revolutionary pharmaceutical protein derived from a scarce species of limpet that only lives in the northeast Pacific, Megathura crenulata, more commonly known as the great or giant keyhole limpet. The exceedingly complex structure and size of the KLH molecule has placed it well beyond the capabilities of even the most advanced synthetic production technologies, meaning the only source for this extremely useful carrier protein is this scarce organism, which lives in only one region of the earth’s waters, an increasingly endangered ocean habitat. KLH is already in use across a wide variety of both research and therapeutic vaccine applications whenever developers can get their hands on enough of the stuff, due to a significant litany of advantages offered by the molecule which simply cannot be found elsewhere or replicated using synthetic alternatives.

What really sets Stellar apart within this niche industry is their world-leading, proprietary aquaculture technology that allows them to sustainably farm giant keyhole limpets and extract an abundant supply of GMP-grade Stellar KLH™ without harming the organism. KLH is eagerly sought after for its ability to carry peptides, typically small proteins of low molecular weight and other drug molecules that do not elicit an immune response on their own. Some of the most significant advantages of this molecule as a carrier protein are its established track record of being extremely safe in the human body, an exceptionally large molecular size with numerous epitope (the part of an antigen that is recognized by the immune system) binding sites for maximized antigen conjugation, and a proven ability to function as a high-efficiency carrier in multiple different applications.

With the granting of an FDA Breakthrough Therapy Designation for a KLH-based immunotherapy compound earlier this year in March, developed by Celldex Therapeutics (NASDAQ: CLDX), which is studying its application in adults suffering from a type of brain cancer known as GBM (EGFRvIII-positive glioblastoma), Stellar Biotechnologies (OTC: SBOTF) (TSXV: KLH) is now extremely well positioned, given that this will likely turn out to be one of the historically most important milestones for validating the KLH-conjugate approach in immunotherapy. The company is aggressively moving to strengthen its overall market presence and really capitalize on the emerging realization throughout the industry of the vast potential of this immune-stimulating protein, and its potential applications across a whole host of immunotherapeutic markets.

The company has now announced a crucial move to up-sell KLH into said markets through a greatly expanded online presence, pushing the company’s corporate communications channels further out into the realm of social media, with a concerted effort to provide the relevant educational content and information about Stellar’s game-changing technology, as well as keeping everyone updated on the company’s constant innovations and activities. The plan is to branch out from the main corporate site www.stellarbiotech.com, leveraging the enormous wealth of scientific and clinical data compiled at www.klhsite.org, in order to establish a bold presence across the three main social media vectors. Google’s (NASDAQ: GOOGL) rapidly growing Google+ framework, which is arguably one of the best ways to increase search visibility in the business world due to its native dovetailing with Google’s ever-changing algorithms, via the “+StellarBiotech” handle, as well as through the still enormously popular venue Facebook (NASDAQ:FB) via the company’s www.facebook.com/StellarBiotech page, and of course by using Twitter (NYSE:TWTR), via their @StellarBiotech account.

Keeping investors and key industry players alike up to date through consistent communication of the company’s activities, as well as routinely pushing relevant data regarding industry developments and the important role Stellar’s KLH technology plays, will no doubt be fundamentally important to the company’s overall marketing strategy. Investors should keep a close eye on Stellar Biotechnologies as their social media footprint takes shape and KLH cements an increasingly frontline role in immunotherapy.

For more information, visit www.stellarbiotechnologies.com

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.